Related Experiment Video

Updated: Jul 12, 2025

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China
08:42

Cox-Maze IV Procedure Concomitant with Valvular Surgery In Situs Inversus Dextrocardia: A Single-Center Experience in China

Published on: February 11, 2022

3.5K

Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Smita Scholtz1, Volker Rudolph1, Jan-Christian Reil1

  • 1Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie, Herz und Diabeteszentrum NRW, Ruhr-Universität Bochum, 32545 Bad Oeynhausen, Germany.

Journal of Clinical Medicine
|October 28, 2023
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) treatment is evolving. Mavacamten, a novel myosin inhibitor, shows promise in reducing left ventricular outflow tract obstruction and improving cardiac function, offering a new therapeutic avenue beyond surgical myectomy and alcohol septal ablation.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a genetic heart muscle disease causing thickened left ventricular walls.
  • Left ventricular outflow tract (LVOT) obstruction and diastolic dysfunction are common, impacting patient symptoms and prognosis.
  • Current treatments for symptomatic obstructive HCM include surgical myectomy and alcohol septal ablation.

Purpose of the Study:

  • To review current evidence on alcohol septal ablation for obstructive HCM.
  • To examine preclinical and clinical data for mavacamten, a novel myosin inhibitor, in treating obstructive HCM.
  • To discuss the potential of mavacamten to revolutionize HCM therapeutic strategies.

Main Methods:

  • Review of existing literature on alcohol septal ablation.
  • Analysis of preclinical studies on mavacamten's mechanism of action.
  • Evaluation of clinical trial data for mavacamten in obstructive HCM patients.

Main Results:

  • Mavacamten targets the underlying actin-myosin cross-bridging pathology in HCM.
  • Mavacamten effectively reduces LVOT obstruction.
  • Mavacamten demonstrates potential benefits for diastolic function, cardiac structure, and microcirculation.

Conclusions:

  • Mavacamten represents a new class of drugs for obstructive HCM.
  • This myosin inhibitor offers a targeted approach to HCM pathophysiology.
  • Mavacamten has the potential to significantly alter treatment paradigms for obstructive HCM.

Keywords:
alcohol septal ablationhypertrophic cardiomyopathyleft ventricular outflow tract obstructionmavacamtenmyosin inhibitorseptal reduction therapy

More Related Videos

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

6.4K
Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

14.0K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
12
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
12
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
15
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
18